Author details

Full Name

Celia C LaBranche

Affiliation

ORCID

Career Start Year

1990

Papers

207

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
37044090	Germline-targeting HIV-1 Env vaccination induces VRC01-class antibodies with rare insertions.	Cell Rep Med	2023
37824545	Correction: HIV-1-neutralizing antibody induced by simian adenovirus- and poxvirus MVA-vectored BG505 native-like envelope trimers.		2023
37986885	Germline-targeting SOSIP trimer immunization elicits precursor CD4 binding-site targeting broadly neutralizing antibodies in infant macaques.	bioRxiv	2023
37553348	Intradermal but not intramuscular modified vaccinia Ankara immunizations protect against intravaginal tier2 simian-human immunodeficiency virus challenges in female macaques.	Nat Commun	2023
37153584	Cholera toxin B scaffolded, focused SIV V2 epitope elicits antibodies that influence the risk of SIVmac251 acquisition in macaques.	Front Immunol	2023
36882405	Direct intranodal tonsil vaccination with modified vaccinia Ankara vaccine protects macaques from highly pathogenic SIVmac251.		2023
34962990	Frequent Development of Broadly Neutralizing Antibodies in Early Life in a Large Cohort of Children With Human Immunodeficiency Virus.	J Infect Dis	2022
35714165	A cellular trafficking signal in the SIV envelope protein cytoplasmic domain is strongly selected for in pathogenic infection.	PLoS Pathog	2022
35709309	Broad coverage of neutralization-resistant SIV strains by second-generation SIV-specific antibodies targeting the region involved in binding CD4.	PLoS Pathogens	2022
35449174	Persistent immunogenicity of integrase defective lentiviral vectors delivering membrane-tethered native-like HIV-1 envelope trimers.	npj Vaccines	2022
35615712	Erratum: Parallel Induction of CH505 B Cell Ontogeny-Guided Neutralizing Antibodies and tHIVconsvX Conserved Mosaic-Specific T Cells against HIV-1.	Molecular Therapy - Methods and Clinical Development	2022
35922441	Identification of IOMA-class neutralizing antibodies targeting the CD4-binding site on the HIV-1 envelope glycoprotein.	Nat Commun	2022
35536018	Vertical HIV-1 Transmission in the Setting of Maternal Broad and Potent Antibody Responses.	Journal of Virology	2022
36405776	Adjuvants influence the maturation of VRC01-like antibodies during immunization.	iScience	2022
36395347	Complementary antibody lineages achieve neutralization breadth in an HIV-1 infected elite neutralizer.	PLoS Pathog	2022
36560823	Recombinant Simian Varicella Virus-Simian Immunodeficiency Virus Vaccine Induces T and B Cell Functions and Provides Partial Protection against Repeated Mucosal SIV Challenges in Rhesus Macaques.		2022
35235790	Structure-guided changes at the V2 apex of HIV-1 clade C trimer enhance elicitation of autologous neutralizing and broad V1V2-scaffold antibodies.	Cell Rep	2022
34669426	The Glycan Hole Area of HIV-1 Envelope Trimers Contributes Prominently to the Induction of Autologous Neutralization.	Journal of Virology	2022
35214753	E4orf1 Suppresses -Deleted Adenovirus Vaccine-Induced Immune Responses.	Vaccines	2022
35228534	High thermostability improves neutralizing antibody responses induced by native-like HIV-1 envelope trimers.	npj Vaccines	2022
35003053	Polyclonal Broadly Neutralizing Antibody Activity Characterized by CD4 Binding Site and V3-Glycan Antibodies in a Subset of HIV-1 Virus Controllers.	Frontiers in Immunology	2021
34019795	Fab-dimerized glycan-reactive antibodies are a structural category of natural antibodies.	Cell	2021
33536254	Virus Control in Vaccinated Rhesus Macaques Is Associated with Neutralizing and Capturing Antibodies against the SHIV Challenge Virus but Not with V1V2 Vaccine-Induced Anti-V2 Antibodies Alone.	Journal of Immunology	2021
33786368	Sulfoglycodendrimer Therapeutics for HIV-1 and SARS-CoV-2.	Advanced Therapeutics	2021
34266981	A yeast expressed RBD-based SARS-CoV-2 vaccine formulated with 3M-052-alum adjuvant promotes protective efficacy in non-human primates.	Sci Immunol	2021
33563983	Immunofocusing and enhancing autologous Tier-2 HIV-1 neutralization by displaying Env trimers on two-component protein nanoparticles.	npj Vaccines	2021
33980592	A Derivative of the D5 Monoclonal Antibody That Targets the gp41 N-Heptad Repeat of HIV-1 with Broad Tier-2-Neutralizing Activity.	Journal of Virology	2021
33441339	The immunological impact of adenovirus early genes on vaccine-induced responses in mice and nonhuman primates.	Journal of Virology	2021
34086838	Structural and genetic convergence of HIV-1 neutralizing antibodies in vaccinated non-human primates.	PLoS Pathogens	2021
33554060	Anti-V2 antibodies virus vulnerability revealed by envelope V1 deletion in HIV vaccine candidates.	iScience	2021
34358190	Bispecific Anti-HIV Immunoadhesins That Bind Gp120 and Gp41 Have Broad and Potent HIV-Neutralizing Activity.	Vaccines	2021
33306985	D614G Spike Mutation Increases SARS CoV-2 Susceptibility to Neutralization.		2021
33358977	Lipid-based vaccine nanoparticles for induction of humoral immune responses against HIV-1 and SARS-CoV-2.	Journal of Controlled Release	2021
33431684	The high-affinity immunoglobulin receptor FcÎ³RI potentiates HIV-1 neutralization via antibodies against the gp41 N-heptad repeat.	Proceedings of the National Academy of Sciences of the United States of America	2021
34432859	Antibody responses induced by SHIV infection are more focused than those induced by soluble native HIV-1 envelope trimers in non-human primates.	PLoS Pathogens	2021
34376662	Polyclonal antibody responses to HIV Env immunogens resolved using cryoEM.	Nat Commun	2021
32663192	SIV infection duration largely determines broadening of neutralizing antibody response in macaques.	Journal of Clinical Investigation	2020
31832930	An Engineered Biomimetic MPER Peptide Vaccine Induces Weakly HIV Neutralizing Antibodies in Mice.		2020
32402293	Co-immunization of DNA and Protein in the Same Anatomical Sites Induces Superior Protective Immune Responses against SHIV Challenge.	Cell Reports	2020
32109354	The Impact of Sustained Immunization Regimens on the Antibody Response to Oligomannose Glycans.	ACS Chem Biol	2020
31827000	Impact of T1 CD4 Follicular Helper T Cell Skewing on Antibody Responses to an HIV-1 Vaccine in Rhesus Macaques.	Journal of Virology	2020
32343743	Correction:Â ALVAC-HIV B/C candidate HIV vaccine efficacy dependent on neutralization profile of challenge virus and adjuvant dose and type.	PLoS Pathog	2020
32163525	Engagement of monocytes, NK cells, and CD4+ Th1 cells by ALVAC-SIV vaccination results in a decreased risk of SIVmac251 vaginal acquisition.	PLoS Pathog	2020
32393800	T cell-inducing vaccine durably prevents mucosal SHIV infection even with lower neutralizing antibody titers.	Nat Med	2020
32439962	Glycopeptide epitope facilitates HIV-1 envelope specific humoral immune responses by eliciting T cell help.	Nature Communications	2020
31917969	Optimization and qualification of a functional anti-drug antibody assay for HIV-1 bnAbs.	Journal of Immunological Methods	2020
33681810	An Efficient Microwave-Mediated Synthesis of Hexavalent Sialic Acid Sulfoglycodendrimers as Potential Anti-HIV Agents.	ACS Applied Polymer Materials	2020
33087466	Priming with DNA Expressing Trimeric HIV V1V2 Alters the Immune Hierarchy Favoring the Development of V2-Specific Antibodies in Rhesus Macaques.	Journal of Virology	2020
32584790	Improved killing of HIV-infected cells using three neutralizing and non-neutralizing antibodies.	Journal of Clinical Investigation	2020
33298954	Immunogenicity, safety, and efficacy of sequential immunizations with an SIV-based IDLV expressing CH505 Envs.	npj Vaccines	2020